All Oncology News

CDK4/6 inhibition with palbociclib demonstrated encouraging efficacy in patients with low-grade serous ovarian cancer.

Lorlatinib has received NICE’s recommendation for untreated advanced non–small cell lung cancer.

Proton therapy provides pediatric patients a treatment option that minimizes impact on long-term growth and development.

A new drug application was submitted to Japan’s Ministry of Health, Labour and Welfare for T-DXd plus pertuzumab for HER2-positive breast cancer.

A Data Monitoring Committee confirmed that the safety profile of HyBryte is acceptable and that the agent is not associated with safety concerns in CTCL.

Emerging technologies and process reconsiderations may alleviate time and resource stressors oncology teams face when appealing patient insurance denials.

Paula Rodriguez-Otero, MD, discusses linvoseltamab’s potential role in the management of high-risk smoldering myeloma.

BTK inhibitor therapy improved PFS vs chemoimmunotherapy in NOTCH1-mutated CLL, highlighting the value of NOTCH1 screening to guide treatment selection.

Check out this September recap of OncLive’s coverage of the top news and expert insights in lung cancer.

Vote on the top abstracts and topics to watch in gynecologic and gastrointestinal oncology during the 2025 ESMO Congress.

A genetic factor may explain why some patients with colorectal cancer that has spread to the liver experience liver damage after chemotherapy.

Dato-DXd displayed topline survival benefits in patients with recurrent/metastatic TNBC who could not receive immunotherapy.

The FDA granted priority review to a biologics license applications seeking the approval of Orca-T for select hematologic malignancies.

Phase 2 data showed bevacizumab plus erlotinib active in papillary RCC, with 72% responses in HLRCC-associated and 35% in sporadic disease.

Sacituzumab tirumotecan plus pembrolizumab is currently being evaluated for select patients with TNBC in the phase 3 TroFuse-012 trial.

Martin F. Dietrich, MD, PhD, discusses the potential role of atebimetinib plus chemotherapy in frontline pancreatic cancer.

Maurie Markman, MD, details the lessons learned following results from older clinical trials within the oncology space.

The top 5 OncLive TV videos of the week cover insights in lung cancer, and prostate cancer, myelofibrosis.

The FDA clears maintenance lurbinectedin combination in lung cancer, T-DxD sBLA in HER2-positive breast cancer is accepted for review, and more.

A mogamulizumab-based combination led to complete remission in a patient with CAR-positive T-cell lymphoma with CCR4 overexpression.

Here is your Q4 2025 preview spotlighting 10 FDA decisions to watch, including upcoming PDUFAs for belantamab mafodotin, revumenib, sevabertinib, and more.

Multiple myeloma and non-Hodgkin lymphoma emerge as key hematology topics ahead of ESMO 2025, followed by MPNs and T-cell lymphoma.

Breast cancer experts vote on their most anticipated abstracts on social media ahead of the 2025 ESMO Congress.

The addition of molecular breast imaging to a 3D mammogram more than doubled the ability to find cancer in dense tissue, according to Mayo Clinic investigators.

Early objective responses have been shown with JNJ-1900 plus immune checkpoint inhibitors for recurrent/metastatic HNSCC.

Paxalisib plus pembrolizumab and chemotherapy led to an 86% reduction in tumor burden in a patient with metastatic triple-negative breast cancer.

A real-world analysis shows avelumab plus axitinib is safe and effective in advanced RCC.

GPC3 has the potential to be targeted in patients with HCC with reduced off-target toxicities compared with other targeted agents.

Here is your guide to all therapeutic options that were approved by the FDA in September 2025 spanning tumor types.